TY  - CHAP
M1  - Book, Section
TI  - Leukemias & Other Myeloproliferative Neoplasms
A1  - Damon, Lloyd E.
A1  - Andreadis, Charalambos Babis
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
PY  - 2022
T2  - Current Medical Diagnosis & Treatment 2022
AB  - Myeloproliferative  disorders  are  due  to  acquired  clonal  abnormalities  of  the  hematopoietic  stem  cell  (eFigure  13–19).  Since  the  stem  cell  gives  rise  to  myeloid,  erythroid,  and  platelet  cells,  qualitative  and  quantitative  changes  are  seen  in  all  of  these  cell  lines.  Classically,  the  myeloproliferative  disorders  produce  characteristic  syndromes  with  well-defined  clinical  and  laboratory  features  (Tables  13–13  and  13–14).  However,  these  disorders  are  grouped  together  because  they  may  evolve  from  one  into  another  and  because  hybrid  disorders  are  commonly  seen.  All  of  the  myeloproliferative  disorders  may  progress  to  AML.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/24
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1184165978
ER  -